Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 48 citations in OpenAlex.

1. Moonlighting functions of glucose metabolic enzymes and metabolites in cancer.Nature reviews. Cancer · 2025
   Review
2. Correlation Analysis of Pyroptosis-Related Genes CASP1, NLRP3, AIM2, and NLRP1 With Lung Adenocarcinoma.International journal of genomics · 2025
   Article
3. HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer.Science advances · 2024
   Article
4. Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing's Disease.Frontiers in endocrinology · 2020
   Article

Corrections and comments

• Erratum for
  Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association.2016

Authors and funding

10 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract